Corcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney sold 6,091 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $12.50, for a total transaction of $76,137.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Corcept Therapeutics Incorporated (NASDAQ CORT) traded up 0.15% during trading on Friday, reaching $12.97. 660,723 shares of the company were exchanged. The firm has a 50-day moving average price of $11.86 and a 200-day moving average price of $10.06. The stock has a market capitalization of $1.47 billion, a P/E ratio of 118.99 and a beta of 2.05. Corcept Therapeutics Incorporated has a 1-year low of $5.24 and a 1-year high of $13.25.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, May 1st. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.01. The company had revenue of $27.60 million for the quarter, compared to analyst estimates of $25.53 million. Corcept Therapeutics had a net margin of 13.51% and a return on equity of 33.97%. The firm’s revenue for the quarter was up 71.9% on a year-over-year basis. Equities research analysts predict that Corcept Therapeutics Incorporated will post $0.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “David L. Mahoney Sells 6,091 Shares of Corcept Therapeutics Incorporated (CORT) Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/21/david-l-mahoney-sells-6091-shares-of-corcept-therapeutics-incorporated-cort-stock.html.

Several research firms have recently weighed in on CORT. Piper Jaffray Companies set a $18.00 price target on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Monday, May 15th. BidaskClub downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 15th. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 8th. TheStreet downgraded shares of Corcept Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, May 1st. Finally, Ladenburg Thalmann Financial Services set a $20.00 price target on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Corcept Therapeutics currently has a consensus rating of “Buy” and an average price target of $14.20.

Large investors have recently added to or reduced their stakes in the company. Chicago Equity Partners LLC raised its stake in Corcept Therapeutics by 5.2% in the first quarter. Chicago Equity Partners LLC now owns 54,435 shares of the biotechnology company’s stock worth $597,000 after buying an additional 2,680 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in Corcept Therapeutics by 5.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 56,303 shares of the biotechnology company’s stock worth $617,000 after buying an additional 2,992 shares during the period. American International Group Inc. raised its stake in Corcept Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 46,000 shares of the biotechnology company’s stock worth $504,000 after buying an additional 3,042 shares during the period. Teachers Advisors LLC raised its stake in Corcept Therapeutics by 6.3% in the first quarter. Teachers Advisors LLC now owns 196,026 shares of the biotechnology company’s stock worth $2,148,000 after buying an additional 11,566 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Corcept Therapeutics during the first quarter worth about $153,000. Institutional investors own 53.52% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.